Igenomix UK Revenue and Competitors
Estimated Revenue & Valuation
- Igenomix UK's estimated annual revenue is currently $1.2M per year.
- Igenomix UK's estimated revenue per employee is $84,000
Employee Data
- Igenomix UK has 14 Employees.
- Igenomix UK grew their employee count by -18% last year.
Igenomix UK Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.6M | 90 | -36% | $14.1M | N/A |
#2 | $83.2M | 468 | -3% | $251M | N/A |
#3 | $14M | 100 | 1% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $30.3M | 197 | -6% | N/A | N/A |
#6 | $0.1M | 6 | -25% | $2.6M | N/A |
#7 | $45.1M | 293 | 2% | N/A | N/A |
#8 | $4.8M | 43 | -7% | N/A | N/A |
#9 | $399.3M | 2037 | 40% | N/A | N/A |
#10 | $44M | 286 | 4% | N/A | N/A |
What Is Igenomix UK?
IGENOMIX UK provides advanced services in reproductive genetics. Our broad experience and strong history of research & development make us one of the global leaders in this field. We use cutting-edge technology to provide the best services, from embryo testing (PGS/PGD), endometrial receptivity and microbiome analysis (ERA, EMMA, ALICE), to carrier screening (CGT) and our very highly-regarded non-invasive prenatal test (NACE).
keywords:N/A
N/A
Total Funding
14
Number of Employees
$1.2M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Igenomix UK News
... Eurofins LifeCodexx GmbH., IGENOMIX INDIA, 10x Genomics, NIPD Genetics, Progenity, Inc., Invitae Corporation, ... UK: +44 208 089 1725.
... especially in developed countries such as U.S., U.K., France, Germany, ... INC., PerkinElmer Inc, Eurofins LifeCodexx AG, and IGENOMIX.
KNMP.nl) and the NICE British National Formulary (www.bnf.nice.org.uk). ... consultancy for ObsEva, Merck, Merck KGaA, iGenomix and Guerbet.
Other Companies in Guildford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.7M | 14 | N/A | N/A |
#2 | $1.1M | 14 | -7% | N/A |
#3 | $3.1M | 16 | N/A | N/A |
#4 | $2.1M | 17 | N/A | N/A |
#5 | $3.5M | 19 | 0% | N/A |